Targeting both B7-H3 and EGFR could improve responses to OXP chemotherapy both in vitro and in vivo, indicating that CRC patients might benefit from a dual blockade of B7-H3 and EGFR [94]. The gene discussed is EGFR; the disease is colorectal carcinoma.